Sitagliptin

Sitagliptin is a DPP‑4 inhibitor with modest HbA1c reduction and cardiovascular neutrality; it has no demonstrated heart failure outcome benefit. DPP-4 inhibitors may in fact exacerbate heart failure symptoms through oedema worsening. This is not the best drug for Mr. Green.

Please go back and re-consider. 

  • Πολλαπλασιάζοντας ¼ με 4. [undo]
  • Explore the further investigation and management of chronic disease appropriate with patient’s needs [undo]
  • (1) prophase, (2) interphase, (3) telophase, (4) prometaphase, (5) metaphase and (6) anaphase [undo]
  • Lansoprazole [undo]
  • Το σενάριο με πολλά παιδιά [undo]
  • Pegvisomant [undo]
  • Brentuximab-Vedotin+AVD [undo]
  • Descripción 3 [undo]
  • IDENTIFICAREA BIOMOLECULELOR [undo]
  • Metolazone [undo]
  • AV block [undo]
  • Focus only on glucose control [undo]
  • Περιγραφή των κυττάρων 1 [undo]
  • Αγνοήστε την πιθανότητα, γιατί ήδη γνωρίζουμε ότι η κυστική ίνωση είναι υπολειπόμενη. [undo]
  • Pioglitazone [undo]
  • Option 3 [undo]
  • Ca să nu rupem sau murdărim halatul în afara laboratorului [undo]
  • Το λίπασμα προστέθηκε ενώ το παράθυρο του ζυγού ήταν ανοιχτό, επιτρέποντας στα ρεύματα αέρα να επηρεάσουν τη μέτρηση. [undo]
  • Περιγραφή των κυττάρων 3 [undo]
  • Sitagliptin [undo]

Map: Michael Green_GEMD_1 (1115)
Node: 21101
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway